1-Deoxynojirimycin Derivatives Stabilize Alpha-Glucosidase for Pompe Disease
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Pompe disease, such as enzyme replacement therapy and gene therapy, face challenges like rapid enzyme degradation, high costs, and limited effectiveness in penetrating connective tissue and the blood-brain barrier, while small molecule inhibitors can cause adverse effects by depleting essential glycolipids.
Innovation Solution
Administering 1-deoxynojirimycin (1-DNJ) and its derivatives, like N-butyl-1-deoxynojirimycin (NB-DNJ), to stabilize and enhance the activity of the α-glucosidase enzyme, facilitating its proper conformation and trafficking to lysosomes, thereby reducing glycogen accumulation in muscle tissues.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If enzyme replacement therapy is used to treat Pompe disease, then the deficiency in acid α-glucosidase can be addressed, but the therapy faces rapid enzyme degradation and limited effectiveness in penetrating connective tissue and the blood-brain barrier
Solution Approach 1:
The patent uses small molecule inhibitors as intermediaries to indirectly enhance acid α-glucosidase activity. These molecules bind to the enzyme and stabilize it, preventing rapid degradation while avoiding the need for direct enzyme replacement that suffers from penetration barriers. This mediator approach allows therapeutic effect without the limitations of direct enzyme therapy.
Solution Approach 2:
The invention changes the physical-chemical parameters of the treatment by using small molecule compounds that can cross the blood-brain barrier and connective tissue, unlike large protein enzymes. These small molecules bind to and stabilize the acid α-glucosidase enzyme, altering its stability parameter and extending its duration of action in vivo.
2Reliability
If small molecule inhibitors are used to treat Pompe disease, then enzyme activity can be enhanced, but essential glycolipids may be depleted causing adverse effects
Solution Approach 1:
The patent applies local quality by designing small molecule inhibitors with specific structural features that allow them to bind selectively to acid α-glucosidase without affecting other enzymes that process glycolipids. This selective binding enhances the target enzyme activity while avoiding the harmful depletion of essential glycolipids that would occur with non-specific inhibition.
Solution Approach 2:
The invention uses small molecule copies or analogs of natural substrates that can bind to the acid α-glucosidase active site and stabilize the enzyme, but unlike the actual substrate (glycogen), these molecules do not get metabolized into products that would deplete essential glycolipids. They act as stable mimics that provide therapeutic benefit without the harmful metabolic consequences.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The use of DNJ derivatives significantly increases α-glucosidase activity, providing a therapeutic effect by stabilizing the enzyme and improving muscle function in Pompe disease patients with minimal adverse effects.
Implementation Method 1
Administering 1-deoxynojirimycin (1-DNJ) and its derivatives, like N-butyl-1-deoxynojirimycin (NB-DNJ), to stabilize and enhance the activity of the α-glucosidase enzyme
Data Source
AI summary
The present invention provides a method for increasing the activity of a mutant or wild-type α-glucosidase enzyme in vitro and in vivo by contacting the enzyme with a specific pharmacological chaperone which is a derivative of 1-deoxynojirimycin. The invention also provides a method for the treatment of Pompe disease by administration of chaperone small molecule compound which is a derivative of 1-deoxynojirimycin. The 1-deoxynojirimycin derivative is substituted at the N or C1 position. Combination therapy with replacement α-glucosidase gene or enzyme is also provided.